ArticleEJNMMI research2018
Biokinetic and dosimetric aspects of
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Preclinical Theranostic Profiling of [Molecules (Basel, Switzerland) · 2025Article
- Novel Aptamer Strategies in Combating Bacterial Infections: From Diagnostics to Therapeutics.Pharmaceutics · 2024Review
- Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review.Journal of cancer research and clinical oncology · 2024Review
- Diagnostic and Dosimetry Features of [Molecular imaging and biology · 2023Article
- An Overview of In Vitro Assays ofDiagnostics (Basel, Switzerland) · 2023Review
- Editorial:Frontiers in medicine · 2023Article
- Cellular lethal damage ofFrontiers in medicine · 2023Article
- Advancements in the use of Auger electrons in science and medicine during the period 2015-2019.International journal of radiation biology · 2023Review
- Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent.Journal of clinical medicine · 2022Review
- Imaging zinc trafficking in vivo by positron emission tomography with zinc-62.Metallomics : integrated biometal science · 2022Article
- Recent Advances in Cancer Imaging withNuclear medicine and molecular imaging · 2022Review
- Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.Theranostics · 2022Article
- Article
- Preclinical PET imaging study of lung cancer withAnnals of nuclear medicine · 2020Article
- Monte Carlo track-structure for the radionuclide Copper-64: characterization of S-values, nanodosimetry and quantification of direct damage to DNA.Physics in medicine and biology · 2020Article
- Hypoxia imaging and theranostic potential of [EJNMMI research · 2020Review
- Copper-64 Chloride Exhibits Therapeutic Potential in Three-Dimensional Cellular Models of Prostate Cancer.Frontiers in molecular biosciences · 2020Article
- Radiobiological Characterization ofMolecules (Basel, Switzerland) · 2018Article
- Insights into Trace Metal Metabolism in Health and Disease from PET: "PET Metallomics".Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- Copper-64: a real theranostic agent.Drug design, development and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the present study is to evaluate the kinetics and dosimetry of
resultsThe mean effective half-life of
conclusionsDosimetry showed that the dose absorbed by PCa recurrences/metastases per administrated activity was low. The dosimetric study performed does not take into account the possible therapeutic effect of the Auger electrons. Clinical trials are needed to evaluate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.